Drug Profile
ZD 6003
Latest Information Update: 05 Feb 2008
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Granulocyte colony-stimulating factors; Immunotherapies
- Mechanism of Action Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Jan 2008 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 18 May 1995 Suspended-Preclinical for Cancer in United Kingdom (unspecified route)